The future of EPAC-targeted therapies: Agonism versus antagonism

Trends in Pharmacological Sciences

Volumn 36, Issue 4, 2015, Pages 203-214

  Parnell, Euan ^a   Palmer, Timothy M ^b   Yarwood, Stephen J ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF BRADFORD   (United Kingdom)

Author keywords

agonism; antagonism; cAMP; diabetes; EPAC; inflammation

Indexed keywords

CYCLIC AMP; GUANINE NUCLEOTIDE EXCHANGE FACTOR; RAPGEF3 PROTEIN, HUMAN; RAPGEF4 PROTEIN, HUMAN;

AGONISTS; ANIMAL; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG DELIVERY SYSTEM; FORECASTING; HUMAN; METABOLISM; PROTEIN SECONDARY STRUCTURE; PROTEIN TERTIARY STRUCTURE; TRENDS;

ANIMALS; CYCLIC AMP; DRUG DELIVERY SYSTEMS; FORECASTING; GUANINE NUCLEOTIDE EXCHANGE FACTORS; HUMANS; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY;

EID: 84939971446     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2015.02.003     Document Type: Review

References (132)

1. J. de Rooij Epac is a Rap1 guanine-nucleotide-exchange factor directly activated by cyclic AMP Nature 396 1998 474 477
2. H. Kawasaki A family of cAMP-binding proteins that directly activate Rap1 Science 282 1998 2275 2279
3. D.A. Walsh An adenosine 3′,5′-monophosphate-dependent protein kinase from rabbit skeletal muscle J. Biol. Chem. 243 1968 3763 3765
4. K. Matulef, and W.N. Zagotta Cyclic nucleotide-gated ion channels Annu. Rev. Cell Dev. Biol. 19 2003 23 44
5. T. Brand The cAMP-binding Popdc proteins have a redundant function in the heart Biochem. Soc. Trans. 42 2014 295 301
6. 2-agonists Respir. Med. 95 Suppl. B 2001 S2 S6
7. 2-adrenoceptor agonists in asthma management Respir. Med. 99 2005 152 170
8. C. Burnouf, and M.P. Pruniaux Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs Curr. Pharm. Des. 8 2002 1255 1296
9. J. de Rooij Mechanism of regulation of the Epac family of cAMP-dependent RapGEFs J. Biol. Chem. 275 2000 20829 20836
10. H. Rehmann Structure of Epac2 in complex with a cyclic AMP analogue and RAP1B Nature 455 2008 124 127
11. H. Rehmann Structure of the cyclic-AMP-responsive exchange factor Epac2 in its auto-inhibited state Nature 439 2006 625 628
12. R. Selvaratnam The auto-inhibitory role of the EPAC hinge helix as mapped by NMR PLoS ONE 7 2012 e48707
13. R. Selvaratnam Mapping allostery through the covariance analysis of NMR chemical shifts Proc. Natl. Acad. Sci. U.S.A. 108 2011 6133 6138
14. R. Selvaratnam The projection analysis of NMR chemical shifts reveals extended EPAC autoinhibition determinants Biophys. J. 102 2012 630 639
15. R. Das Dynamically driven ligand selectivity in cyclic nucleotide binding domains J. Biol. Chem. 284 2009 23682 23696
16. R. Das Entropy-driven cAMP-dependent allosteric control of inhibitory interactions in exchange proteins directly activated by cAMP J. Biol. Chem. 283 2008 19691 19703
17. S. Boulton Tapping the translation potential of cAMP signalling: molecular basis for selectivity in cAMP agonism and antagonism as revealed by NMR Biochem. Soc. Trans. 42 2014 302 307
18. T. Shibasaki Essential role of Epac2/Rap1 signaling in regulation of insulin granule dynamics by cAMP Proc. Natl. Acad. Sci. U.S.A. 104 2007 19333 19338
19. G.G. Holz Epac: a new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic β-cell Diabetes 53 2004 5 13
20. 2+ release and exocytosis in pancreatic β-cells J. Biol. Chem. 278 2003 8279 8285
21. H. Hatakeyama Two cAMP-dependent pathways differentially regulate exocytosis of large dense-core and small vesicles in mouse β-cells J. Physiol. 582 2007 1087 1098
22. M. Schmidt Epac and the cardiovascular system Curr. Opin. Pharmacol. 7 2007 193 200
23. 2+ mobilization in cardiac myocytes J. Biol. Chem. 282 2007 5488 5495
24. 2+ATPase isoform 3b and Rap 1b: interrelation and regulation in physiopathology Biochem. J. 332 1998 173 181
25. 2+/calmodulin kinase signalling pathway in rat cardiac myocytes J. Physiol. 583 2007 685 694
26. O.G. Chepurny PKA-dependent potentiation of glucose-stimulated insulin secretion by Epac activator 8-pCPT-2′-O-Me-cAMP-AM in human islets of Langerhans Am. J. Physiol. Endocrinol. Metab. 298 2010 E622 E633
27. A.K. Kai Exchange protein activated by cAMP 1 (Epac1)-deficient mice develop beta-cell dysfunction and metabolic syndrome FASEB J. 27 2013 4122 4135
28. Y. Yang EPAC null mutation impairs learning and social interactions via aberrant regulation of miR-124 and Zif268 translation Neuron 73 2012 774 788
29. J. Yan Enhanced leptin sensitivity, reduced adiposity, and improved glucose homeostasis in mice lacking exchange protein directly activated by cyclic AMP isoform 1 Mol. Cell. Biol. 33 2013 918 926
30. 2+ in female mouse islets stimulated by glucose and tolbutamide Endocrinology 155 2014 3274 3287
31. M. Zhang Progesterone receptor membrane component 1 is a functional part of the glucagon-like peptide-1 (GLP-1) receptor complex in pancreatic β cells Mol. Cell. Proteomics 13 2014 3049 3062
32. E.A. Suarez Incretin-mimetic therapies and pancreatic disease: a review of observational data Curr. Med. Res. Opin. 30 2014 2471 2481
33. M. Metrich Role of the cAMP-binding protein Epac in cardiovascular physiology and pathophysiology Pflugers Arch. 459 2010 535 546
34. M. Metrich Epac mediates β-adrenergic receptor-induced cardiomyocyte hypertrophy Circ. Res. 102 2008 959 965
35. 2+ leak and arrhythmia Circulation 127 2013 913 922
36. J.S. Pober Elevated cyclic AMP inhibits endothelial cell synthesis and expression of TNF-induced endothelial leukocyte adhesion molecule-1, and vascular cell adhesion molecule-1, but not intercellular adhesion molecule-1 J. Immunol. 150 1993 5114 5123
37. M.J. Sanz Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation Br. J. Pharmacol. 135 2002 1872 1881
38. A.N. Orekhov Primary culture of human aortic intima cells as a model for testing antiatherosclerotic drugs. Effects of cyclic AMP, prostaglandins, calcium antagonists, antioxidants, and lipid-lowering agents Atherosclerosis 60 1986 101 110
39. M. Shoji IL-6 mobilizes bone marrow-derived cells to the vascular wall, resulting in neointima formation via inflammatory effects J. Atheroscler. Thromb. 21 2014 304 312
40. M. Naya Plasma interleukin-6 and tumor necrosis factor-α can predict coronary endothelial dysfunction in hypertensive patients Hypertens. Res. 30 2007 541 548
41. W. Zhang Interleukin 6 underlies angiotensin II-induced hypertension and chronic renal damage Hypertension 59 2012 136 144
42. P.M. Ridker Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men Circulation 101 2000 1767 1772
43. C. Fanelli, and R. Aronoff Restenosis following coronary angioplasty Am. Heart J. 119 1990 357 368
44. T. Suzuki Raised interleukin 6 concentrations as a predictor of postangioplasty restenosis Heart 83 2000 578
45. D.A. Sukovich Expression of interleukin-6 in atherosclerotic lesions of male ApoE-knockout mice: inhibition by 17β-estradiol Arterioscler. Thromb. Vasc. Biol. 18 1998 1498 1505
46. L.H. Wei Interleukin-6 promotes cervical tumor growth by VEGF-dependent angiogenesis via a STAT3 pathway Oncogene 22 2003 1517 1527
47. M. Jougasaki Statins suppress interleukin-6-induced monocyte chemo-attractant protein-1 by inhibiting Janus kinase/signal transducers and activators of transcription pathways in human vascular endothelial cells Br. J. Pharmacol. 159 2010 1294 1303
48. P.C. Heinrich Principles of interleukin (IL)-6-type cytokine signalling and its regulation Biochem. J. 374 2003 1 20
49. R. Kleemann Cytokines and atherosclerosis: a comprehensive review of studies in mice Cardiovasc. Res. 79 2008 360 376
50. N. Sarwar Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies Lancet 379 2012 1205 1213
51. A.D. Hingorani, and J.P. Casas The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis Lancet 379 2012 1214 1224
52. J. Scheller, and S. Rose-John The interleukin 6 pathway and atherosclerosis Lancet 380 2012 338
53. T. Hou Roles of IL-6-gp130 signaling in vascular inflammation Curr. Cardiol. Rev. 4 2008 179 192
54. H. Schuett Transsignaling of interleukin-6 crucially contributes to atherosclerosis in mice Arterioscler. Thromb. Vasc. Biol. 32 2012 281 290
55. M. Hashizume IL-6/sIL-6R trans-signalling, but not TNF-α induced angiogenesis in a HUVEC and synovial cell co-culture system Rheumatol. Int. 29 2009 1449 1454
56. A. Yoshimura SOCS proteins, cytokine signalling and immune regulation Nat. Rev. Immunol. 7 2007 454 465
57. J.C. Tan, and R. Rabkin Suppressors of cytokine signaling in health and disease Pediatr. Nephrol. 20 2005 567 575
58. A. Sasaki Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain Genes Cells 4 1999 339 351
59. N.J. Kershaw Reconstruction of an active SOCS3-based E3 ubiquitin ligase complex in vitro: identification of the active components and JAK2 and gp130 as substrates Growth Factors 32 2014 1 10
60. X. Liang Multiple roles of SOCS proteins: differential expression of SOCS1 and SOCS3 in atherosclerosis Int. J. Mol. Med. 31 2013 1066 1074
61. G. Ortiz-Munoz Suppressors of cytokine signaling modulate JAK/STAT-mediated cell responses during atherosclerosis Arterioscler. Thromb. Vasc. Biol. 29 2009 525 531
62. B.A. Croker IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3 Immunol. Cell Biol. 90 2012 124 129
63. A. Stahl SOCS3 is an endogenous inhibitor of pathologic angiogenesis Blood 120 2012 2925 2929
64. D. Jo Intracellular protein therapy with SOCS3 inhibits inflammation and apoptosis Nat. Med. 11 2005 892 898
65. C. Recio Suppressor of cytokine signaling 1-derived peptide inhibits Janus kinase/signal transducers and activators of transcription pathway and improves inflammation and atherosclerosis in diabetic mice Arterioscler. Thromb. Vasc. Biol. 34 2014 1953 1960
66. S. Xiang Suppressor of cytokine signaling 3 is a negative regulator for neointimal hyperplasia of vein graft stenosis J. Vasc. Res. 51 2014 132 143
67. W.A. Sands Exchange protein activated by cyclic AMP (Epac)-mediated induction of suppressor of cytokine signaling 3 (SOCS-3) in vascular endothelial cells Mol. Cell. Biol. 26 2006 6333 6346
68. J. Wiejak The role of c-Jun in controlling the EPAC1-dependent induction of the SOCS3 gene in HUVECs FEBS Lett. 588 2014 1556 1561
69. S.J. Yarwood Identification of CCAAT/enhancer-binding proteins as exchange protein activated by cAMP-activated transcription factors that mediate the induction of the SOCS-3 gene J. Biol. Chem. 283 2008 6843 6853
70. M.R. Kooistra Epac1 regulates integrity of endothelial cell junctions through VE-cadherin FEBS Lett. 579 2005 4966 4972
71. X. Cullere Regulation of vascular endothelial barrier function by Epac, a cAMP-activated exchange factor for Rap GTPase Blood 105 2005 1950 1955
72. C.M. Beckers Driving Rho GTPase activity in endothelial cells regulates barrier integrity Thromb. Haemost. 103 2010 40 55
73. N.V. Bogatcheva Molecular mechanisms of thrombin-induced endothelial cell permeability Biochemistry (Mosc.) 67 2002 75 84
74. M. Aslam cAMP controls the restoration of endothelial barrier function after thrombin-induced hyperpermeability via Rac1 activation Physiol. Rep. 2 2014 e12175
75. R.C. Hewer PKA and Epac synergistically inhibit smooth muscle cell proliferation J. Mol. Cell. Cardiol. 50 2011 87 98
76. T.E. Kimura Inhibition of Egr1 expression underlies the anti-mitogenic effects of cAMP in vascular smooth muscle cells J. Mol. Cell. Cardiol. 72 2014 9 19
77. M. Bond Rho GTPase, Rac1, regulates Skp2 levels, vascular smooth muscle cell proliferation, and intima formation in vitro and in vivo Cardiovasc. Res. 80 2008 290 298
78. B. Gong Exchange protein directly activated by cAMP plays a critical role in bacterial invasion during fatal rickettsioses Proc. Natl. Acad. Sci. U.S.A. 110 2013 19615 19620
79. U. Yokoyama Prostaglandin E2-activated Epac promotes neointimal formation of the rat ductus arteriosus by a process distinct from that of cAMP-dependent protein kinase A J. Biol. Chem. 283 2008 28702 28709
80. K.W. van Hooren The Epac-Rap1 signaling pathway controls cAMP-mediated exocytosis of Weibel-Palade bodies in endothelial cells J. Biol. Chem. 287 2012 24713 24720
81. G.K. Gupta Suppressor of cytokine signaling-3 and intimal hyperplasia in porcine coronary arteries following coronary intervention Exp. Mol. Pathol. 91 2011 346 352
82. K. Dhar SOCS3 promotor hypermethylation and STAT3-NF-κB interaction downregulate SOCS3 expression in human coronary artery smooth muscle cells Am. J. Physiol. Heart Circ. Physiol. 304 2013 H776 H785
83. H. Rehmann Ligand-mediated activation of the cAMP-responsive guanine nucleotide exchange factor Epac J. Biol. Chem. 278 2003 38548 38556
84. L.M. Brown Allosteric inhibition of Epac: computational modeling and experimental validation to identify allosteric sites and inhibitors J. Biol. Chem. 289 2014 29148 29157
85. J.M. Enserink A novel Epac-specific cAMP analogue demonstrates independent regulation of Rap1 and ERK Nat. Cell Biol. 4 2002 901 906
86. M.J. Vliem 8-pCPT-2′-O-Me-cAMP-AM: an improved Epac-selective cAMP analogue Chembiochem 9 2008 2052 2054
87. S. Fukuhara Cyclic AMP potentiates vascular endothelial cadherin-mediated cell-cell contact to enhance endothelial barrier function through an Epac-Rap1 signaling pathway Mol. Cell. Biol. 25 2005 136 146
88. M. Métrich Functional characterization of the cAMP-binding proteins Epac in cardiac myocytes Pharmacol. Rep. 61 2009 146 153
89. H. Poppe Cyclic nucleotide analogs as probes of signaling pathways Nat. Methods 5 2008 277 278
90. L. Herfindal Off-target effect of the Epac agonist 8-pCPT-2′-O-Me-cAMP on P2Y12 receptors in blood platelets Biochem. Biophys. Res. Commun. 437 2013 603 608
91. ATP channels Annu. Rev. Physiol. 60 1998 667 687
92. 125I-labeled glyburide analog J. Biol. Chem. 267 1992 14928 14933
93. C.L. Zhang The cAMP sensor Epac2 is a direct target of antidiabetic sulfonylurea drugs Science 325 2009 607 610
94. T. Tsalkova Exchange protein directly activated by cyclic AMP isoform 2 is not a direct target of sulfonylurea drugs Assay Drug Dev. Technol. 9 2011 88 91
95. K.J. Herbst Direct activation of Epac by sulfonylurea is isoform selective Chem. Biol. 18 2011 243 251
96. T. Tsalkova A fluorescence-based high-throughput assay for the discovery of exchange protein directly activated by cyclic AMP (EPAC) antagonists PLoS ONE 7 2012 e30441
97. M. Almahariq A novel EPAC-specific inhibitor suppresses pancreatic cancer cell migration and invasion Mol. Pharmacol. 83 2013 122 128
98. H. Chen Identification and characterization of small molecules as potent and specific EPAC2 antagonists J. Med. Chem. 56 2013 952 962
99. T. Tsalkova Isoform-specific antagonists of exchange proteins directly activated by cAMP Proc. Natl. Acad. Sci. U.S.A. 109 2012 18613 18618
100. H. Chen 5-Cyano-6-oxo-1,6-dihydro-pyrimidines as potent antagonists targeting exchange proteins directly activated by cAMP Bioorg. Med. Chem. Lett. 22 2012 4038 4043
101. H. Rehmann Epac-inhibitors: facts and artefacts Sci. Rep. 3 2013 3032
102. R. Lorenz The cAMP/Epac1/Rap1 pathway in pancreatic carcinoma Pancreas 37 2008 102 103
103. D. Courilleau Identification of a tetrahydroquinoline analog as a pharmacological inhibitor of the cAMP-binding protein Epac J. Biol. Chem. 287 2012 44192 44202
104. A. Kraemer Dynamic interaction of cAMP with the Rap guanine-nucleotide exchange factor Epac1 J. Mol. Biol. 306 2001 1167 1177
105. D. Courilleau The (R)-enantiomer of CE3F4 is a preferential inhibitor of human exchange protein directly activated by cyclic AMP isoform 1 (Epac1) Biochem. Biophys. Res. Commun. 440 2013 443 448
106. L.M. Brown Identification and validation of modulators of exchange protein activated by cAMP (Epac) activity: structure-function implications for Epac activation and inhibition J. Biol. Chem. 289 2014 8217 8230
107. K. Bacallao, and P.V. Monje Opposing roles of PKA and EPAC in the cAMP-dependent regulation of Schwann cell proliferation and differentiation [corrected] PLoS ONE 8 2013 e82354
108. A. Mediero Activation of EPAC1/2 is essential for osteoclast formation by modulating NFκB nuclear translocation and actin cytoskeleton rearrangements FASEB J. 28 2014 4901 4913
109. A. Dawn The central role of cAMP in regulating Plasmodium falciparum merozoite invasion of human erythrocytes PLoS Pathog. 10 2014 e1004520
110. T. Nagata Oncostatin M, an interleukin-6 family cytokine, upregulates matrix metalloproteinase-9 through the mitogen-activated protein kinase kinase-extracellular signal-regulated kinase pathway in cultured smooth muscle cells Arterioscler. Thromb. Vasc. Biol. 23 2003 588 593
111. T.X. Xie Stat3 activation regulates the expression of matrix metalloproteinase-2 and tumor invasion and metastasis Oncogene 23 2004 3550 3560
112. K. Leslie Cyclin D1 is transcriptionally regulated by and required for transformation by activated signal transducer and activator of transcription 3 Cancer Res. 66 2006 2544 2552
113. H.D. Woolson Selective inhibition of cytokine-activated extracellular signal-regulated kinase by cyclic AMP via Epac1-dependent induction of suppressor of cytokine signalling-3 Cell. Signal. 21 2009 1706 1715
114. S. Sehrawat Role of Epac1, an exchange factor for Rap GTPases, in endothelial microtubule dynamics and barrier function Mol. Biol. Cell 19 2008 1261 1270
115. S.H. Ross Ezrin is required for efficient Rap1-induced cell spreading J. Cell Sci. 124 2011 1808 1818
116. S.V. Consonni cAMP regulates DEP domain-mediated binding of the guanine nucleotide exchange factor Epac1 to phosphatidic acid at the plasma membrane Proc. Natl. Acad. Sci. U.S.A. 109 2012 3814 3819
117. S.J. Yarwood Microtubule-associated proteins (MAPs) regulate cAMP signalling through exchange protein directly activated by cAMP (EPAC) Biochem. Soc. Trans. 33 2005 1327 1329
118. C. Liu The interaction of Epac1 and Ran promotes Rap1 activation at the nuclear envelope Mol. Cell. Biol. 30 2010 3956 3969
119. M. Gloerich The nucleoporin RanBP2 tethers the cAMP effector Epac1 and inhibits its catalytic activity J. Cell Biol. 193 2011 1009 1020
120. Y. Li The RAP1 guanine nucleotide exchange factor Epac2 couples cyclic AMP and Ras signals at the plasma membrane J. Biol. Chem. 281 2006 2506 2514
121. G. Kang cAMP sensor Epac as a determinant of ATP-sensitive potassium channel activity in human pancreatic beta cells and rat INS-1 cells J. Physiol. 573 2006 595 609
122. I. Dzhura Phospholipase links Epac2 activation to the potentiation of glucose-stimulated insulin secretion from mouse islets of Langerhans Islets 3 2011 3
123. E.P. Kwan Interaction between Munc13-1 and RIM is critical for glucagon-like peptide-1 mediated rescue of exocytotic defects in Munc13-1 deficient pancreatic β-cells Diabetes 56 2007 2579 2588
124. 2+ sensor in pancreatic β-cells. Involvement of cAMP-GEFII. Rim2.Piccolo complex in cAMP-dependent exocytosis J. Biol. Chem. 277 2002 50497 50502
125. M. Almahariq Exchange protein directly activated by cAMP modulates regulatory T-cell-mediated immunosuppression Biochem. J. 465 2015 295 303
126. T. Takahashi Antidiabetic sulfonylureas and cAMP cooperatively activate Epac2A Sci. Signal. 6 2013 ra94
127. H. Rehmann Epac2: a sulfonylurea receptor? Biochem. Soc. Trans. 40 2012 6 10
128. I. McPhee Cyclic nucleotide signalling: a molecular approach to drug discovery for Alzheimer's disease Biochem. Soc. Trans. 33 2005 1330 1332
129. A. Glading KRIT-1/CCM1 is a Rap1 effector that regulates endothelial cell cell junctions J. Cell Biol. 179 2007 247 254
130. C.W. Wilson Rasip1 regulates vertebrate vascular endothelial junction stability through Epac1-Rap1 signaling Blood 122 2013 3678 3690
131. A.A. Birukova Epac/Rap and PKA are novel mechanisms of ANP-induced Rac-mediated pulmonary endothelial barrier protection J. Cell. Physiol. 215 2008 715 724
132. Y. Su Regulatory subunit of protein kinase A: structure of deletion mutant with cAMP binding domains Science 269 1995 807 813